Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Earnings

Review historical estimates and see whether a company has beaten or missed expectations.

Last Close
Jul 17 04:00PM ET
21.77
Dollar change
-1.04
Percentage change
-4.56
%
IndexRUT P/E- EPS (ttm)-2.92 Insider Own3.80% Shs Outstand64.41M Perf Week7.56%
Market Cap1.40B Forward P/E- EPS next Y-2.87 Insider Trans-2.10% Shs Float61.97M Perf Month43.41%
Income-165.00M PEG- EPS next Q-0.66 Inst Own74.79% Short Float13.03% Perf Quarter48.60%
Sales62.30M P/S22.51 EPS this Y-4.56% Inst Trans-4.24% Short Ratio7.60 Perf Half Y149.66%
Book/sh5.76 P/B3.78 EPS next Y-3.55% ROA-38.30% Short Interest8.07M Perf Year120.79%
Cash/sh6.88 P/C3.16 EPS next 5Y- ROE-52.33% 52W Range4.22 - 24.38 Perf YTD110.95%
Dividend Est.- P/FCF- EPS past 5Y-59.00% ROI-42.14% 52W High-10.70% Beta2.22
Dividend TTM- Quick Ratio5.57 Sales past 5Y27.29% Gross Margin75.73% 52W Low415.88% ATR (14)1.52
Dividend Ex-Date- Current Ratio5.57 EPS Y/Y TTM1.63% Oper. Margin-287.47% RSI (14)59.10 Volatility8.86% 8.68%
Employees284 Debt/Eq0.08 Sales Y/Y TTM2.25% Profit Margin-264.84% Recom1.33 Target Price28.42
Option/ShortYes / Yes LT Debt/Eq0.06 EPS Q/Q-59.61% Payout- Rel Volume0.83 Prev Close22.81
Sales Surprise-45.30% EPS Surprise-11.85% Sales Q/Q-60.58% EarningsJul 11 AMC Avg Volume1.06M Price21.77
SMA205.81% SMA5024.94% SMA20087.95% Trades Volume915,819 Change-4.56%
Date Action Analyst Rating Change Price Target Change
Jun-26-23Resumed Oppenheimer Outperform $25
Mar-09-23Initiated Barclays Overweight $20
Feb-28-23Initiated Oppenheimer Outperform $25
Oct-11-22Initiated Morgan Stanley Equal-Weight $11
May-31-22Upgrade Wells Fargo Equal Weight → Overweight $25
Feb-10-22Initiated Wells Fargo Equal Weight $28
Dec-29-21Initiated H.C. Wainwright Buy $62
Oct-14-21Initiated SVB Leerink Outperform $50
Jun-04-21Resumed Robert W. Baird Outperform $45 → $46
Apr-30-21Resumed Piper Sandler Overweight $60
Jul-16-24 12:00PM
Jul-11-24 05:10PM
04:00PM
Jul-08-24 07:00AM
Jun-20-24 07:02PM
05:26PM Loading…
05:26PM
Jun-19-24 05:05AM
Jun-17-24 04:06PM
08:45AM
07:40AM
Jun-16-24 05:30AM
Jun-10-24 07:00AM
May-29-24 07:00AM
May-28-24 07:00AM
May-20-24 04:41PM
04:00PM Loading…
04:00PM
10:21AM
May-14-24 10:00AM
07:39AM
May-07-24 07:00AM
Apr-16-24 06:21PM
Apr-11-24 11:38PM
04:00PM
Apr-10-24 11:53AM
09:29AM
08:31AM
08:10AM
07:00AM
Apr-09-24 01:15PM
07:00AM
07:00AM Loading…
Apr-03-24 07:00AM
Apr-02-24 07:00AM
Mar-25-24 07:00AM
Mar-20-24 09:40AM
Mar-11-24 07:00AM
Mar-06-24 04:00PM
Mar-05-24 04:30PM
Feb-23-24 06:20AM
Feb-16-24 07:04PM
Feb-15-24 05:10PM
04:00PM
Feb-01-24 04:01PM
10:01AM
Jan-16-24 04:01PM
Jan-08-24 07:00AM
Jan-02-24 04:01PM
Dec-21-23 05:01PM
Dec-13-23 04:32PM
Dec-11-23 12:00PM
Dec-04-23 04:01PM
Nov-07-23 04:01PM
Nov-02-23 09:00AM
Nov-01-23 04:01PM
Oct-18-23 09:35AM
Oct-14-23 06:01AM
Oct-12-23 05:15PM
04:01PM
Oct-11-23 07:09AM
Oct-05-23 09:35AM
Oct-04-23 09:35AM
Sep-28-23 10:00AM
Sep-20-23 09:30AM
Sep-15-23 12:00PM
09:55AM
Sep-11-23 12:10PM
Sep-08-23 05:32AM
Sep-07-23 07:00AM
Aug-31-23 10:12PM
04:01PM
Aug-02-23 05:01AM
Jul-24-23 09:55AM
Jul-15-23 08:12AM
Jul-13-23 05:15PM
04:01PM
Jul-11-23 10:00AM
Jun-29-23 10:00AM
Jun-14-23 07:00AM
May-25-23 06:28AM
May-24-23 09:55AM
May-09-23 04:01PM
May-04-23 09:55AM
Apr-19-23 06:05AM
Apr-18-23 09:55AM
Apr-17-23 02:30PM
Apr-13-23 05:15PM
04:01PM
Apr-11-23 04:01PM
Mar-30-23 10:00AM
Mar-21-23 10:05AM
03:49AM
Mar-20-23 12:17PM
09:00AM
08:30AM
Mar-17-23 09:22AM
Mar-14-23 04:45PM
Mar-06-23 04:01PM
Feb-27-23 11:57AM
Feb-09-23 05:35PM
04:15PM
Feb-08-23 04:01PM
Nurix Therapeutics, Inc. is a clinical stage biopharmaceutical company. It engages in the business of discovering, developing, and commercializing innovative small molecules and antibody therapies based on the modulation of cellular protein levels as a novel treatment approach for cancer, inflammatory conditions, and other challenging diseases. The company was founded by John Kuriyan, Michael Rape, and Arthur Weiss in 2009 and is headquartered in San Francisco, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Ring ChristineChief Legal OfficerJul 01 '24Option Exercise1.865,76010,71425,598Jul 01 06:35 PM
Ring ChristineChief Legal OfficerJul 01 '24Sale20.815,760119,83719,838Jul 01 06:35 PM
van Houte HansChief Financial OfficerJun 20 '24Sale20.0120,000400,21648,333Jun 20 04:58 PM
Ring ChristineChief Legal OfficerJun 13 '24Option Exercise1.861,8643,46721,702Jun 13 06:39 PM
Ring ChristineChief Legal OfficerJun 13 '24Sale17.021,86431,72119,838Jun 13 06:39 PM
Ring ChristineChief Legal OfficerJun 12 '24Option Exercise1.861,9003,53421,738Jun 12 07:30 PM
Ring ChristineChief Legal OfficerJun 12 '24Sale17.011,90032,31919,838Jun 12 07:30 PM
Ring ChristineChief Legal OfficerJun 05 '24Option Exercise1.8640074420,238Jun 05 06:01 PM
Ring ChristineChief Legal OfficerJun 05 '24Sale17.004006,80119,838Jun 05 06:01 PM
Ring ChristineChief Legal OfficerJun 03 '24Option Exercise1.861,5962,96921,434Jun 03 06:36 PM
Ring ChristineChief Legal OfficerJun 03 '24Sale17.011,59627,15319,838Jun 03 06:36 PM
van Houte HansChief Financial OfficerMay 02 '24Sale12.833,49944,87868,333May 02 06:01 PM
Hansen GwennChief Scientific OfficerApr 30 '24Option Exercise0.005,206041,608Apr 30 06:33 PM
van Houte HansChief Financial OfficerApr 30 '24Option Exercise0.004,886073,219Apr 30 06:33 PM
Ring ChristineChief Legal OfficerApr 30 '24Option Exercise0.003,924021,351Apr 30 06:33 PM
Hansen GwennChief Scientific OfficerApr 30 '24Sale12.042,00724,16939,601Apr 30 06:33 PM
Ring ChristineChief Legal OfficerApr 30 '24Sale12.041,51318,22019,838Apr 30 06:33 PM
van Houte HansChief Financial OfficerApr 30 '24Sale12.041,38716,70371,832Apr 30 06:33 PM
van Houte HansChief Financial OfficerFeb 16 '24Sale10.026,81268,22368,333Feb 16 07:20 PM
van Houte HansChief Financial OfficerJan 30 '24Option Exercise0.004,886076,816Jan 30 06:53 PM
Hansen GwennChief Scientific OfficerJan 30 '24Option Exercise0.005,207038,736Jan 30 06:52 PM
Ring ChristineChief Legal OfficerJan 30 '24Option Exercise0.003,924019,187Jan 30 06:52 PM
Hansen GwennChief Scientific OfficerJan 30 '24Sale7.992,33418,64936,402Jan 30 06:52 PM
Ring ChristineChief Legal OfficerJan 30 '24Sale7.991,76014,06317,427Jan 30 06:52 PM
van Houte HansChief Financial OfficerJan 30 '24Sale7.991,67113,35275,145Jan 30 06:53 PM
van Houte HansChief Financial OfficerDec 20 '23Sale10.003,54135,42171,930Dec 21 05:19 PM
van Houte HansChief Financial OfficerDec 19 '23Sale10.0010,906109,09375,471Dec 20 04:55 PM
Hansen GwennChief Scientific OfficerOct 31 '23Sale5.201,6338,48733,529Nov 01 04:40 PM
Ring ChristineChief Legal OfficerOct 31 '23Sale5.201,2326,40315,263Nov 01 04:40 PM
van Houte HansChief Financial OfficerOct 31 '23Sale5.201,0805,61386,377Nov 01 04:41 PM
van Houte HansChief Financial OfficerOct 30 '23Option Exercise0.004,886087,457Nov 01 04:41 PM
Hansen GwennChief Scientific OfficerOct 30 '23Option Exercise0.005,207035,162Nov 01 04:40 PM
Ring ChristineChief Legal OfficerOct 30 '23Option Exercise0.003,924016,495Nov 01 04:40 PM
Hansen GwennChief Scientific OfficerJul 31 '23Sale9.651,88418,18929,955Aug 01 04:26 PM
Ring ChristineGeneral CounselJul 31 '23Sale9.651,42013,71012,544Aug 01 04:27 PM
van Houte HansChief Financial OfficerJul 31 '23Sale9.651,24512,02082,571Aug 01 04:28 PM
van Houte HansChief Financial OfficerJul 30 '23Option Exercise0.004,886083,816Aug 01 04:28 PM
Ring ChristineGeneral CounselJul 30 '23Option Exercise0.003,924013,964Aug 01 04:27 PM
Hansen GwennChief Scientific OfficerJul 30 '23Option Exercise0.005,207031,839Aug 01 04:26 PM